Clinical Trial Update: CART-19 Cells For MRD Positive CD19+ ALL [Phase 2, Phase 3]

View source ↗

Summary

An update on CART-19 cell therapy for MRD-positive CD19+ acute lymphoblastic leukemia, conducted across Phase 2 and Phase 3. The sponsor is Fujian Medical Unive…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia

Drugs mentioned

• CART-19 cells (CAR-T cell therapy targeting CD19)

Snippet

Sponsor: Fujian Medical University | Conditions: Acute Lymphoblastic Leukemia | Phase 2, Phase 3 | Status: UNKNOWN